John Alam, MD – Chief Executive Officer of CervoMed Inc., was recently a guest on Benzinga's All-Access. CervoMed is a clinical-stage company dedicated to the development and commercialization of targeted drug treatments for neurodegenerative diseases with a focus on the early stages of the disease process. Mr. Alam spoke of the promising topline results from the ongoing phase 2b trial of its lead drug candidate.
